Topics

Nosocomial Infections Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975

03:29 EST 1 Feb 2020 | BioPortfolio Report Blog

FirstView Market Insight Nosocomial Infections Market Review, Epidemiology And Market Forecast 2029 provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights.The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and market revenue during study period 20182029.A nosocomial infection is contracted because of an infection or toxin that exists in a certain location, such as a hospital. People now use nosocomial infections interchangeably with the terms healthcare associated infections HAIs and hospitalacquired infections. For a HAI, the infection must not be present before someone has been under medical care.

One of the most common wards where HAIs occur is the intensive care unit ICU, where doctors treat serious diseases. About 1 in 10 of the people admitted to a hospital will contract a HAI. They're also associated with significant morbidity, mortality, and hospital costs.For a HAI, the infection must occur:

up to 48 hours after hospital admission

up to 3 days after discharge

up to 30 days after an operation

in a healthcare facility when someone was admitted for reasons other than the infection

Symptoms of HAIs will vary by type. The most common types of HAIs are:

urinary tract infections UTIs

surgical site infections

gastroenteritis

meningitis

pneumonia

The symptoms for these infections may include:

discharge from a wound

fever

cough, shortness of breathing

burning with urination or difficulty urinating

headache

nausea, vomiting, diarrhea Bacteria, fungus, and viruses can cause HAIs. Bacteria alone cause about 90 percent of these cases. Many people have compromised immune systems during their hospital stay, so they're more likely to contract an infection.Of the HAIs, P. aeruginosa accounts for 11 percent and has a high mortality and morbidity rate.


Bacteria, fungi, and viruses spread mainly through persontoperson contact. This includes unclean hands, and medical instruments such as catheters, respiratory machines, and other hospital tools. HAI cases also increase when there's excessive and improper use of antibiotics. This can lead to bacteria that are resistant to multiple antibiotics.


Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines

Epidemiology Forecast

This section encompasses information on the incidence and prevalence of disease in EU5, US Japan. It also provides historical, current and forecasted estimates of diagnosed/treatable patient population.

Existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning, regulatory milestones and patent exclusivity. It gives insight into the potential therapeutic targets for drug development. The section also covers major events and latest happenings, deals and collaborations.

Market Size

This section of report will address the major issues, on the size and total addressable market share. This will help the companies to understand and visualize their business prospects and make major decisions based on the historical, current and forecasted market share across the globe. Analyze the commercial potential of the product as well as the disease/therapy area.


Market Trends Unmet needs

This section of the report helps to understand the market trend and opportunities by analyzing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analyzing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.


List of products

Piperacillintazobactam meropenem amikacin vancomycin cephalosporins teicoplanin daptomycin colistin linezolid

Original Article: Nosocomial Infections Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975

NEXT ARTICLE

More From BioPortfolio on "Nosocomial Infections Market Review, Epidemiology And Market Forecast 2029 [Published by First View Insight] Prices from USD $2975"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...